Description

Lucentis Solution for Injections 10 mg/ml. 0.23 ml. (2 needles)

Ingredients

Lucentis contains the active ingredient Ranibizumab at a concentration of 10 mg/ml.

Dosage

Lucentis is administered via intravitreal injection. The usual dose is 0.5 mg (0.05 ml) once a month.

Indications

Lucentis is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Contraindications

Lucentis is contraindicated in patients with ocular or periocular infections.

Directions

Lucentis should be administered by a healthcare professional as an intravitreal injection. Patients should be monitored for signs of endophthalmitis.

Scientific Evidence

Studies have shown the efficacy of Lucentis in improving visual acuity and reducing retinal thickness in patients with neovascular AMD. Clinical trials have demonstrated its superiority over photodynamic therapy and placebo in the treatment of this condition.

Additional Information

It is important to inform patients about the potential risks associated with intravitreal injections, including retinal detachment and cataract formation. Regular follow-up appointments are crucial to monitor the response to treatment and detect any adverse effects early.

Lucentis works by inhibiting vascular endothelial growth factor (VEGF), a key mediator of angiogenesis and vascular permeability in the eye. By blocking VEGF, Lucentis helps reduce abnormal blood vessel growth and leakage, thereby improving retinal function and visual outcomes.

Clinical trials have also compared the effectiveness of Lucentis with other anti-VEGF agents in the treatment of retinal diseases. Research published in the American Journal of Ophthalmology has shown that Lucentis is non-inferior to Bevacizumab in terms of visual acuity outcomes in patients with neovascular AMD.